Ulixertinib (BVD-523)

ulixertinib · Bayer

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Ulixertinib (BVD-523), covering 2026-02-27 to 2026-02-27. Get the full timeline:

Most recent: Clinical Trial Update: Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas [EARLY_Phase 1]